WO1994021124A1 - Removal of selected factors from whole blood or its components - Google Patents
Removal of selected factors from whole blood or its components Download PDFInfo
- Publication number
- WO1994021124A1 WO1994021124A1 PCT/US1994/002541 US9402541W WO9421124A1 WO 1994021124 A1 WO1994021124 A1 WO 1994021124A1 US 9402541 W US9402541 W US 9402541W WO 9421124 A1 WO9421124 A1 WO 9421124A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silica
- blood
- composition
- heparin
- citrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3431—Substitution fluid path upstream of the filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3643—Priming, rinsing before or after use
- A61M1/3644—Mode of operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3673—Anticoagulant coating, e.g. Heparin coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3643—Priming, rinsing before or after use
Definitions
- This invention concerns the treatment and prevention of conditions evidenced by the presence of selected factors in a patient's blood. More
- the invention concerns the treatment and prevention of septic shock syndrome and capillary leak syndrome, diseases which correlate with the presence of selected factors such as cytokines, serotonin, histamine, and/or activated complement components in a patient's blood.
- the invention is used to remove selected factors such as pharmaceuticals from a patient's blood.
- the method of the invention is performed by extracorporeally contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but
- HSA human serum albumin
- Septic shock is a serious syndrome which most often accompanies gram-negative, and sometimes gram- positive, bacteremia.
- septic shock may occur in virtually any typical infection, e.g., viral, fungal, and rickettsial; it may also result from severe trauma or tissue injury.
- gram-negative rods such as Enterobacteriaceae and Pseudomonaceae are normally found in the digestive tract, however, these bacteria can invade the bloodstream of patients receiving
- Septic shock usually results from a series of events triggered by bacteremia during which bacterial cell wall substances (endotoxin in gram-negative
- Incipient septic shock is characterized by body temperature extremes (hypothermia or fever), orthostatic blood pressure decrease, decreasing urine output, edema, falling serum albumin concentration, development of a metabolic acidosis, elevated serum lactate,
- Septic shock typically advances in two stages.
- patients demonstrate symptoms characteristic of vasomotor effects that follow cytokine and ACTH/endorphin release, kallikrein/kinin system activation, and
- microvascular dysfunction a fall in intravascular blood volume, decline in cardiac output, disseminated
- Cytokines therefore, are involved in the generation of sepsis and septic shock. Cytokines are intercellular mediators. For example, cytokines play a role in the generation of an immune response, such as in an immune response to an infection or infectious organism.
- CLS Capillary leak syndrome
- the vascular injury and organ impairment produced by CLS resemble the impairments produced in septic shock.
- the therapies are directed to the maintenance of blood pressure, organ perfusion and oxygenation.
- therapies often involve assisted ventilation, and often include volume replacement with plasma expanders such as 5% albumin, isotonic saline, or lactated Ringer's solution. Sufficient volume is provided to raise the pulmonary capillary wedge pressure to the high normal range. When simple volume replacement is not sufficient, vasopressor compounds such as dopamine, dobutamine, or norepinephrine may be used. Antiinflammatory drugs such as methylprednisolone, sodium succinate and
- antiprostaglandins for suppression of inflammatory damage, may be used as needed.
- Other therapies include antimicrobial agents, corticosteroids, anticoagulants, and diuretics.
- Acute renal failure is broadly defined as a rapid deterioration in renal function sufficient to result in accumulation of nitrogenous wastes in the body.
- the causes of such deterioration include renal
- hypoperfusion obstructive uropathy
- intrinsic renal disease such as acute glomerulonephritis
- myoglobinuria usually with the acute onset of weakness or paralysis: Crush injury or infarction of a large mass of muscle; excessive muscular contraction; acute idiopathic polymyositis and viral myositis; or, drugs and toxins.
- myoglobin and other muscle proteins enter the bloodstream and may appear in the urine, whereupon the urine becomes dark red or burgundy colored.
- Myoglobin may be separated from hemoglobin by spectroscopy or radioimmunoassay. When myoglobinuria is severe, renal damage may ensue and lead to anuria.
- myoglobinuria results in acute renal failure is uncertain. Most likely, the mechanism of renal damage is not simply a mechanical obstruction of the tubules by precipitated myoglobin. Typically, the treatment for acute renal failure corresponding with myoglobinuria addresses the underlying cause of the myoglobinuria, if remedial. The treatment for anuria would be the same as with anuria following surgical shock.
- silica-based materials have been chemically modified silica. The chemical modifications are directed to providing a silica material that will not lead to blood coagulation, and resultant clogging/failure of the silica column. It was believed that a device that utilized unmodified silica would lead to failure, since chemical modifications on the silica were understood to be necessary to accomplish the desired results. Chemical modification of silica is, however, an intricate process that adds significantly to the cost of the resultant materials.
- the chemically modified silica materials have not been fully successful at providing the desired dual result of removing selected factors from blood, while avoiding clotting within, and resulting failure of, the silica- containing device. Accordingly, there has been a need for a cost efficient and effective silica material for use in removing selected factors from a patient's blood.
- the present invention addresses treatment of whole blood or plasma to lower the circulating levels of certain unwanted selected factors (such as cytokines, complement molecules, serotonin, histamine, cholesterol molecules, myoglobin or a component thereof, angiogenesis factor, or pharmaceuticals) in the blood by physical or physico-chemical adsorption of those factors on a
- the treatment is extracorporeal, alternatively the treatment may comprise an in-dwelling catheter.
- various toxic effects of the selected factors are avoided or lessened.
- Pretreated silica forms an aspect of the invention, as does a device containing the silica.
- a preferred method of the invention is a process for lowering the circulating levels of selected factors such as cytokines, lymphokines, or other low molecular weight inflammatory mediators such as histamine, serotonin, anaphylatoxins, etc. in whole blood, by contacting that blood with a porous silica material which has been treated with a silica pretreating agent.
- Cytokines play an important role in producing the clinical signs and symptoms of sepsis and septic shock. Accordingly, cytokines are comprised within the variety of selected factors and are a preferred selected factor to be removed in accordance with the present invention.
- the process is desirably used for the prevention or treatment of septic shock or other diseases caused by the selected factors.
- An object of the invention is to process blood to effect a clinically favorable response. In addition, the invention produces less than 1% hemolysis.
- the invention has also been used to remove pharmaceuticals from patient's blood.
- the silica is amorphous, granular, not chemically modified, and retained in a binder such as a matrix, or retained within a device so as to prevent loss into the patient.
- a binder such as a matrix
- An anticoagulation regimen is also set forth which is advantageously used in
- Figures 1A and 1B show schematic diagrams of a system in which the inventive process may take place.
- Figure 2A shows the results of cytokine
- Figure 2B shows the results of cytokine adsorption based on recirculation through a device in accordance with the invention.
- Figures 3A and 3B show the removal of serotonin and histamine, respectively, from blood plasma by use of a silica column.
- Figures 4A, 4B, 4C and 4D are graphs showing, respectively, white blood cell, red blood cell and platelet recovery, and Figure 4D shows percent hemolysis of citrated whole blood after recirculating 10-12 times through a test column. Figures 4A-D show the results from experiments wherein silica column was not
- Figures 5A, 5B, and 5C are graphs showing the recovery of white blood cells, red blood cells, and platelets, respectively, from citrated blood, using a number of different surface- treating candidates.
- Figure 5D compares heparinized and citrated blood, utilizing columns pretreated with HSA.
- Figures 6A, 6B, and 6C are graphs depicting the hemolysis of citrated whole blood using saline (control), heparin silica pretreatment, and HSA silica pretreatment, respectively.
- Figure 6D compares hemolysis between citrated and heparinized blood when applied to columns pretreated with HSA.
- Figure 7 is a detailed graph of the pressure versus time and flow behavior of normal young pig
- Figure 8A depicts the pressure-versus-time profiles for normal young pig subjects #17-#19, and #23; these subjects underwent five hours of treatment using a combination of citrate and heparin for anticoagulation.
- Figure 8B corresponds to Figure 8A, yet depicts the pressure-versus-time profile for normal young pig subject #19, in greater detail.
- Figure 9 shows the pressure-flow-time profiles for the six normal young pig subjects which had undergone a five-hour hemoperfusion procedure with a device in accordance with the present invention. All procedures used a combination of citrate and heparin for
- Figure 10 shows the pressure-time profiles of healthy and septic subjects which had successfully undergone six hours of blood processing with a device in accordance with the invention, using a combined citrate and heparin anticoagulation regimen.
- the present invention relates to the removal of selected factors comprising cytokines, lymphokines or other low molecular weight inflammatory mediators such as histamine, serotonin, or anaphylatoxin, from whole blood or plasma.
- the invention is used for the treatment of septic shock or capillary leak syndrome.
- a patient's whole blood or plasma is contacted with a composition comprising silica and a surface treatment material, preferably human serum albumin (HSA).
- HSA human serum albumin
- the treatment is extracorporeal, alternatively the treatment may comprise an in-dwelling catheter.
- the silica used in the composition of the invention is not chemically modified. Further, the composition is understood to result in substantially no chemical modification of the silica it comprises.
- the present invention is used to lower the content of cytokines, cytokines such as are found in conjunction with septic shock or capillary leak syndrome (CLS).
- the invention is also used to lower the concentrations of other bioactive materials such as histamine, serotonin, and anaphylatoxins (C3a and C5a) and various other substances addressed, e.g., in Figures 2A, 2B, 3A and 3B.
- the method of the present invention will be used to lower the IL-1 and IL-8 content in the blood of a patient experiencing CLS. Accordingly, the invention may be utilized to control the incidence and severity of capillary leak syndrome.
- the process may be used either alone or in conjunction with various forms of chemotherapy to lower the concentration of tumor necrosis factor in a patient's blood.
- the preferred silica suitable for use in this invention comprises chemically unmodified amorphous silica suspension, typically termed silica gel. It is believed that silica parameters of surface area and pore size determine suitability of the silica in the
- the silica has a surface area between about 150 m 2 /g and 1000 m 2 /g, more preferably between 200 m 2 /g and 600 m 2 /g. Additionally, it is preferred that the silica has between 0.5 cc/g and
- the silica has porosity between 0.8 cc/g and 1.5 cc/g.
- the silica particles have an average diameter between about 50 and 250 microns for treatment of septic shock, and up to 1 mm for other applications. Accordingly, PQ10150 silica obtained from PQ, Inc., Conshohocken, PA has been found to be suitable for use in the invention.
- the preferred amorphous silica used in this composition is particulate.
- the particulate silica may be in any of a variety of physical shapes (e.g., granular or spherical).
- granular silica is intended a silica from crushed silica.
- spherical silica is intended particulate silica that has been produced to have a substantially rounded contour. However, the shape and size should be selected to allow free flow and to
- Granular silica gel has been used to good effect when the bed is designed so that the superficial velocity of the blood through the device of the invention is less than about 2.5 cm/sec.
- the devices utilized herein were approximately 9.5 cm in diameter.
- the flow rate is about 100-500 ml/min, which corresponds to a superficial velocity of between 0.02 cm/sec and 0.11 cm/sec.
- the flow rate range for the treatment or prevention of capillary leak syndrome is 1-10 liters/min, which
- silica pore diameter there is a relationship between silica pore diameter and the protein species adsorbed.
- silica having a mean pore diameter of 30 ⁇ to 300 ⁇ is suitable for the prevention or treatment of septic shock (whether from gram-positive or gram-negative bacteria), and that a mean pore diameter between about 60 ⁇ and 200 ⁇ is especially suitable.
- silica column was then treated for 10 to 15 minutes with a sterile injectable 5% human serum albumin prepared by diluting sterile injectable 25% human serum albumin with sterile 0.9% sodium chloride USP injectable saline to a 5% solution.
- Pretreatment of the silica was accomplished by either of two protocols. In one protocol, the columns were flushed with 200 to 300 milliliters of the
- pretreatment typically the amount of time it required to set up the citrated or heparinized blood for processing or to connect a patient to the device.
- pretreatment was accomplished by recirculating the injectable 5% human albumin through the column for 10 to 15 minutes. Both protocols for obtaining pretreated silica were equally suitable, and were used
- compositions in accordance with the invention can be prepared.
- a preferred composition in accordance with the invention can be obtained with larger silica-containing columns.
- a composition of the invention has been
- the columns were first flushed with 0.9% sodium chloride, USP injectable saline.
- the columns containing 145gm were flushed with 10 liters of the 0.9% sodium chloride, USP injectable saline.
- the smaller columns containing 20gm were flushed with two liters of the saline solution.
- the saline was provided at a flow rate of 100 to 500 milliliters per minute.
- the saline solution was provided along with citrate, at a flow rate of 5ml/min, in order to remove air and small particles.
- sterile injectable 5% human serum albumin was pumped through the flushed devices at 100 milliliters per minute, along with
- pretreatment of silica can occur by continuous recirculation of the pretreating agent through the silica bed, or by allowing the pretreating agent and silica to stand for a significant period of time.
- composition with the silica granules can be any reasonably prudent concentration of HSA in a carrier.
- any reasonably prudent concentration of HSA in a carrier will be acceptable.
- silica pretreated with heparin was useful in the invention.
- the HSA and heparin pretreatment protocols are analogous.
- heparin-pretreated silica was obtained by flushing a column having a diameter of approximately 3.2 cm and containing 10 grams of silica with 200 to 300 milliliters of a heparin-saline solution. After flushing the device, the device (containing the heparin-saline solution) was left to stand for 10 to 15 minutes.
- silica granules may be precoated and
- Pretreatment of silica can occur by continuous recirculation of the pretreating agent through the silica bed, or by allowing the pretreating agent and silica to stand for a significant period of time.
- significant period of time we mean at least about 10-15 minutes, often the time it takes to completely connect a subject to the device.
- the preferred particles of amorphous silica can readily be placed in a container for the purpose of preparing a device in accordance with the present
- the container can be constructed of any material which can readily undergo steam, chemical, or gamma-irradiation sterilization.
- any material which can readily undergo steam, chemical, or gamma-irradiation sterilization for instance, glass, polycarbonate, polystyrene, polymethylmethacrylate, polyolefins such as polyethylene and polypropylene, are all suitable.
- the silica may be placed between layers of a retaining filters, or placed within a porous solid matrix.
- the solid matrix immobilizes the silica while simultaneously permitting flow of blood and contact with the silica.
- a wide variety of structures are available for providing suitable blood/silica contact, structures which do not cause significant hemolysis. Prudent use of additional filters to retain the silica particles in their container is preferred.
- the pretreated and immobilized silica may be contacted with the blood in a variety of ways.
- FIG. 1A An embodiment of a device suitable for use in the practice of this invention is shown in schematic form in Figure 1A.
- blood enters through line 100 and passes through pump 102.
- Pump 102 supplies sufficient flow rate and pressure to the
- Silica bed 104 has pressure monitoring devices (106 and 108), adjacent its inlet and its outlet,
- the silica bed 104 is
- the blood once it passes through silica bed 104, may be returned to the body through line 110.
- the total volume of the device should be less than about 700 ml for use on human patients.
- silica beds of any other shape capable of functioning in the manner described herein may be used.
- the length-to-diameter ratio of a silica bed should be selected so as to minimize any pressure drop along the silica bed so as to ensure that shear rates remain below the known values that correlate with cellular damage or destruction.
- the pressure drop along a silica bed (and thus the increase in shear rate) is directly proportional to the length of the bed.
- mitigating against use of a short bed is the fact that clearance of a substance from the blood increases with a longer bed.
- composition to adsorb can be assessed by experiments in which a test solution (such as whole blood or plasma) is contacted with the test solution.
- K an equilibrium constant
- An equilibrium constant (K) is defined in units of (ml solution/g composition).
- the capacity of a composition provides a way to estimate the mass of the composition required to remove a certain quantity of material from solution. This approach was used to estimate the mass of silica required to remove cytokines implicated in sepsis and septic shock in humans.
- cytokines and complement solutions of known concentrations of sorbate (cytokines and complement). Radio-labeled cytokines and complement were prepared in 5% HSA buffered (pH 7.2) with sodium bicarbonate (25 mM) and tonicity adjusted with sodium chloride (150 mM). After an equilibration period of 40 minutes (considered sufficient to ensure equilibrium between the solid and liquid phases), each sample
- Table 1 shows typical values (averaged from triplicate experiments) for the equilibrium constants (K) of the cytokines and complement using non- irradiated silica. Equilibrium constants were determined according to known methodologies. It is clear from Table 1 that circulating cytokines will be adsorbed by the silica at different rates. The effect of gamma irradiation on K was examined using two cytokines: interleukin-8 (IL-8) and tumor necrosis factor (TNF- ⁇ ). These results are shown in Table 2, and are the average from experiments performed in triplicate with each of three different lots of silica. Table 2 indicates that gamma irradiation does not affect the capability of the silica to adsorb
- concentration of TNF- ⁇ to sublethal levels from the plasma of a subject For example, for an adult human subject, one would start with a blood circulating level of TNF- ⁇ of lng/ml; the reduction would be approximately 50%.
- the plasma component of the volume of blood corresponding to a typical 70kg subject having a 45% hematocrit was employed.
- the minimum mass of silica required to lower the concentration of TNF- ⁇ to sublethal levels from the plasma of such a subject is approximately 50 grams.
- a device in accordance with the present invention the AIS Cytosorb TM I-A device (Applied Immune Sciences, Inc., Santa Clara, CA) contains 145 grams of silica.
- the extra silica is included for removal of TNF-o; stored in the extravascular compartment, and any newly generated TNF- ⁇ , as well as to accommodate removal of other selected factors (e.g., IL-1, IL-6, etc.).
- the extra silica is included for removal of TNF-o; stored in the extravascular compartment, and any newly generated TNF- ⁇ , as well as to accommodate removal of other selected factors (e.g., IL-1, IL-6, etc.).
- the selected factors e.g., IL-1, IL-6, etc.
- silica were required to reduce TNF- ⁇ to sublethal levels in a juvenile pig subject.
- a starting blood circulating level of TNF- ⁇ was lng/ml; the reduction of TNF- ⁇ would be to approximately 50% of the starting value.
- 20 grams of silica were used in the smaller device, in order to accommodate removal of TNF- ⁇ stored in the extravascular compartment, any newly generated TNF- ⁇ , as well as to accommodate removal of other cytokine species.
- the device discussed above is excellent for adsorbing proteinaceous molecules.
- the device removes significant levels of serotonin; histamine; anaphylatoxins, such as complement molecules C3a and C5a; and cytokines such as interleukin- 1 (IL-1), interleukin-6 (IL-6), and interleukin-8 (IL-8); interferons; or tumor necrosis factor (TNF) from whole blood.
- IL-1 interleukin- 1
- IL-6 interleukin-6
- IL-8 interleukin-8
- TNF tumor necrosis factor
- the invention is also suitable for treating blood components, such as plasma.
- a device containing 145gm of silica (adsorbent) has approximately three times the capacity needed to effect a clinically meaningful reduction of targeted cytokines from a typical 70kg human subject.
- a device comprised of a clear plastic cylindrical housing with an internal diameter of approximately 9.5cm, an internal volume of approximately 600 milliliters, and containing 145gm of silica was used for a series of experiments.
- the device was used in a process according to the invention, to treat young healthy (50-60kg) swine which were provided with either a citrate or a combined citrate and heparin anticoagulation regimen.
- the device was flushed with ten liters of sterile 0.9% sodium chloride USP injectable saline at 100 to 500 milliliters per minute and 5 milliliters per minute of Acid Citrate Dextrose, NIH Formula A (ACDA), to remove air and small particles.
- ACDA Acid Citrate Dextrose
- the device was then flushed with one liter of sterile
- the subjects were first given a bolus injection of 100 units of sterile injectable heparin per kilogram of body weight. After the bolus heparin injection, the arterial and venous lines of the device were attached and secured to vascular access sites on the subject. Injectable heparin and calcium solutions, and any fluid pumps were also attached to their appropriate ports.
- the blood processing procedure utilized an initial flow rate of 100 milliliters per minute of whole blood obtained from one of the central vascular accesses; while 5 milliliters per minute of ACDA, and 40 units of heparin per kilogram of body weight per hour were input through the arterial line, and 100 mg per kilogram per hour of calcium
- chloride was input through another peripheral venous or central venous access port. After 30 minutes of flow at 100 milliliters per minute, the flow rate was increased to 300 milliliters per minute for the duration of the study. After the blood passed through the device, it was returned to the subject in a continuous circuit through another access port.
- Analogous studies were done using juvenile pigs of 2 -10kg in mass.
- a smaller device (discussed above), containing 20 grams of silica, was used to study the juvenile subjects.
- the procedure for preparing the smaller device corresponded to the procedure described for the larger device, however smaller volumes of saline and silica pretreating solutions were used.
- two liters of saline flushing solution, and 0.5 liter of silica pretreating solution were used.
- lower flow rates were used than had been employed with the 600 ml. device.
- the blood flow rates for the smaller device ranged between 30 to 60 milliliters per minute.
- the citrate for subjects treated with the smaller device, the citrate
- anticoagulant was concentrated trisodium citrate in equivalent citrate quantities (0.33 to 1.0 milligram per milliliter of blood) as the ACDA. Concentrated trisodium citrate was used in order to maintain the volume of fluid infused into the 2-10kg subjects within acceptable levels. The 2-10kg subjects could not tolerate the fluid volume required to anticoagulate with an ACDA solution. The dose of heparin used was the same as for subjects treated with the larger device. Calcium chloride was not needed because the subjects treated with the smaller device were able to metabolize citrate and maintain adequate blood ionized calcium. As addressed below in the Examples section, twelve subjects were also
- Figure IB shows a typical system in which the inventive process may be carried out.
- Blood from the patient is introduced into the system by arterial line (200).
- the blood flows by junction (202) where it is mixed with any necessary adjuvants, such as saline, sodium citrate, heparin, or the like, and proceeds to blood pump (204).
- heparin can also be added from a heparin pump (206).
- heparin from heparin pump (206) can be used to pretreat the silica in silica column (208).
- anticoagulated blood is used with the present invention.
- anticoagulating blood when anticoagulating blood, however, one cannot safely achieve anticoagulation to a degree that absolutely assures that no clotting will occur; were the blood to be anticoagulated to this level, the patient would tend to undergo bleeding diatheses.
- clotting may occur within the passageways leading to or from the device, or within the device itself. Clotting may be significant enough to block the flow through the device. More commonly, clotting will not entirely block the device, it will, however, lead to platelet depletion.
- an anticoagulation regimen is advantageously utilized in conjunction with the process of the invention.
- anticoagulants such as citrate, heparin, or a combination of citrate and
- Heparin to the system to manage any clotting that may occur. Heparin may be added both as a bolus at the beginning of the treatment and continuously during the treatment step. Systemic heparin levels suitable for maintaining an activated coagulation time of >200 seconds is desired. Alternatively, citrate levels in a ratio of 1:10 to 1:60 (Acid Citrate Dextrose, NIH Formula A
- FIG. 1A depicts the results of studies comparing the adsorption of various selected factors, based on the use of devices that have 150um and 1mm silica particles. For each selected factor analyzed, a higher percentage of
- devices using granular silica were tested using fresh whole blood (anticoagulated with citrate) to determine the loss of white and red blood cells, as well as loss of platelets.
- Various test devices were used. These devices had different filters, contained either 70- or 135-micron diameter silica particles, and contained either 0, 5 or 10g silica.
- a device without silica in its column was used as a control.
- the device was flushed with saline. Then, blood was recirculated at a volume flow rate of 50 ml/min for the first 120 minutes. Thereafter, th flow rates were increased to 100, 200, 300 and 437 ml/min; at 120, 127, 134, and 140 minutes, respectively. Samples were taken at time 0, and at 15 minute intervals until 120 minutes. Thereafter, and starting at 120 minutes, blood samples were taken immediately before each increase in flow rate, and then immediately before termination of the experiment at 145 minutes.
- Figure 4D shows that a constant flow rate of 50ml/min for 120 minutes that the amount of hemolysis in a saline flushed column is maintained well below the 1% level, a level meeting, e.g., the current U.S. FDA standard for blood transfusion. Thus, this column does not cause significant hemolysis. Additionally, the
- This example examines two different silica pretreating agents, to evaluate the extent of platelet and cell loss during treatment. The results from this experiment were evaluated to determine a preferred manner of treating silica to prevent undesired removal of cells from blood.
- the pretreating materials tested were a 5% solution of human serum albumin (HSA), and 10 U/ml of heparin in saline. A saline solution was used as a control. Data for this study are illustrated in Figures 5A-5C. For this example, test conditions corresponding to those described in Example 3 were employed.
- Figure 5B shows that nearly 100% of the red blood cells (corrected for dilution) were recovered for each of the priming systems.
- Figure 5C demonstrates that the HSA-treated silica had significantly higher platelet recovery
- HSA is a preferred pretreating agent.
- Figure 5D compares citrated and heparinized blood when applied to HSA-treated columns.
- This example evaluates the amount of hemolysis which occurred, as a function of the silica pretreating agent placed with the silica particles. The results from this experiment were evaluated to determine a preferred manner of treating silica to avoid undesired hemolysis.
- Figure 6A depicts results based on priming the column with saline solution.
- Figure 6A shows that significant hemolysis approaching 1% begins to occur during the latter portion of the test, portions of the test during which flow rates were increased.
- Figure 6B shows that, with a heparin prime, the hemolysis reaches nearly 1% at 120 minutes.
- the silica primed with 5% HSA clearly prevented substantial
- Cytosorb T M l-A devices an adult human device
- Cytosorb T M III-A devices a dimensionally similar small-scale device
- the septic juvenile pigs were produced according to a known sepsis model.
- the sepsis model was developed by A. Lee and J. Matson (Lee, A., et al., "Hemofiltration Removes Toxic Mediators and Prolongs Survival in Staphylococcus aureus Sepsis Acute Lung
- the safety of the device was evaluated by careful measurement of physiological, laboratory and histological parameters.
- the physical performance of the device was assessed by pressure measurements, a sensitive indicator of resistance to flow resulting from changes in flow rate, clotting of blood or kinks in the flow path.
- citrate without any additional anticoagulant such as heparin.
- anticoagulation was achieved with citrate alone, the citrate infusion rate was high.
- the citrate regimen might not be well tolerated by smaller individuals. Due to the citrate levels employed, and a potential issue of citrate toxicity, it was desired to pursue a regimen that utilized lower anticoagulant amounts. Thus, regimens utilizing combined citrate and heparin were studied.
- FIG. 8A depicts the pressure- time- flow profiles for normal young pig subjects #17-#19, and #23.
- Each of these experiments employed some combination of citrate and heparin. Accordingly, each subject had a different loading dose, thereafter heparin and citrate solutions were infused. The amount of each anticoagulant infused over time was varied, in order to determine a combination that provided for free flow while employing a minimal amount of each anticoagulant.
- the data derived from these subjects were of use in determining a preferred combination of citrate and heparin
- anticoagulant regimen If clotting occurred, thereby producing a rise in pressure, more heparin, citrate, or both were given to stop the clotting process.
- Figure 8B depicts further studies wherein young pig subject #19 was given both heparin and ACDA.
- the loading dose given to subject #19 was not preferred in that clotting did result.
- the fact that clotting did occur allowed for study of the ability to modulate clotting.
- increasing doses of heparin did not lead to a decrease in the pressure within the device.
- the ACDA yielded a pressure drop.
- the device pressure again began to rise. During this second pressure rise, initially citrate alone was given.
- the preferred combined citrate and heparin anticoagulant regimen was further tested in healthy young pigs, and in healthy and septic juvenile pigs.
- the pressure-time profiles for these experiments in healthy young pigs (#26, #27, #30-#33) using the Cytosorb TM I-A device are shown in Figure 9.
- the pressure- time profiles for these experiments in healthy and septic juvenile pigs using the Cytosorb TM III-A device, along with control data from use of a sham device, are shown in Figure 10.
- Figures 9 and 10 illustrate the pressure- flow-time profiles of healthy and septic subjects which successfully underwent five to six hours of blood
- Figure 9 illustrates the pressure-flow-time profiles for the six normal young pigs which underwent a five-hour hemoperfusion procedure with the Cytosorb T M I-A device.
- Figure 10 illustrates the pressure- flow- time profiles for the six juvenile pigs which underwent a six-hour hemoperfusion procedure with the Cytosorb T M III-A device.
- juvenile pig subject #11 experienced a pressure change due to a clot within the device.
- Formula A at ratios of blood of anticoagulant (V/V) of 60/1 or less for whole blood flow rates of 300 ml/min or less; together with heparin (100 U/kg), given at the onset of the procedure, and heparin given in sufficient quantities as bolus injections or continuous infusion to maintain an activated clotting time of more than 200 seconds.
- Trisodium citrate concentrate in sufficient quantity to provide at least
- citrate per ml of whole blood (equivalent to 0.5-1.5 mg citrate/ml of blood), for flow rates of 300 ml/min or less; together with heparin (100 U/kg) given at the onset of the procedure, and heparin given in sufficient quantities as bolus injections or continuous infusion to maintain an activated clotting time of more than 200 seconds.
- hematological values for the healthy young pigs and juvenile pigs all showed a time-dependent decrease in white blood cells, red blood cells, fibrinogen and platelet counts (Tables 2 and 6). The decreases were due to dilution from priming solution in the device and due to the administration of anticoagulants. These time- dependent changes, when compared to the respective control groups for the healthy young pigs and the septic juvenile pigs, did not produce any clinically significant difference. These results again indicated that the device was not causing any clinically significant loss of blood cells, particularly platelets. The blood chemistry values for both study groups remained, for the most part, unchanged.
- the increase in calcium was the resulted from the use of citrate, a calcium chelating agent, and the concomitant administration of calcium ion as a prophylaxis for hypocalcemia.
- the increase in inorganic phosphorus was most likely the indirect result of citrate binding of calcium, resulting in mobilization from bone by the action of parathyroid hormone.
- the increase in SGOT was very slight and not clinically significant.
- silica When subjected to simulated hemoperfusion or plasma perfusion, silica is understood to adsorb
- silica has not been utilized to remove pharmaceuticals from whole blood or plasma, such as for use in treating drug overdosage.
- the silica composition in accordance with the invention removes pharmaceuticals from whole blood in a manner whereby the blood can be returned to its donor.
- the silica composition can also remove pharmaceuticals from plasma.
- silica PQ10150 sodium silicate gel, PQ Corp., Valley Forge, PA
- a mean particle size 230 ⁇ m
- a surface area of 400 m 2 /g pretreated with human serum albumin or heparin is set forth herein.
- Evaluations are made of pharmaceutical solutions of: 2 ml of plasma containing drugs at 4 different concentrations, or 2 ml of whole blood containing drugs at 4 different concentrations ( (each being serial 50% dilutions of the initial
- compositions such as gentamicin, procainamide, quinidine, insulin, lidocaine,
- amitriptyline desipramine, digoxin, ethosuximide, cocaine, theophylline, phenobarbital, acetaminophen, phenytoin, ethylene glycol, methotrexate, salicylate, thiocyanate and diazepam were evaluated.
- pharmaceutical-saline solutions are produced by adding the pharmaceutical solutions to 1 ml buffered saline (as controls), or by adding the
- compositions to 1 ml of buffered saline containing 0.3 gm of silica composition in accordance with the invention.
- the pharmaceutical-saline solutions are agitated for 40 minutes at room temperature.
- benzodiazepines fluorescence polarization assay for digoxin using a TDX analyzer (Abbott Labs,Abbott Part, IL), and EMIT assay (Syva, San Jose, CA) using Monarch 2000 analyzer (Instrumentation Laboratory) for all other drugs.
- Cocaine levels are measured by Nichols Institute, San Diego, CA, by quantitative radioimmunoassay.
- Insulin levels are measured by Associated Regional and University Pathologists (ARUP) Inc., Salt Lake City, UT, by
- N-acetyl procainamide drug concentration range 2 to 40 ⁇ g/ml
- drug concentration range 2 to 40 ⁇ g/ml drug concentration range 2 to 40 ⁇ g/ml
- quinidine is adsorbed at a low concentration (2 ⁇ g/ml), with adsorption of 75% at the highest concentration (17.75 ⁇ g/ml).
- insulin is adsorbed at a concentration of 5687uU/ml, which decreased to 65% at a concentration of 46640uU/ml. 74% of
- lidocaine is removed (drug concentration range 12 to 100 ⁇ g/ml). 73% of amitriptyline is adsorbed for
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU65176/94A AU680897B2 (en) | 1993-03-16 | 1994-03-08 | Removal of selected factors from whole blood or its components and prevention and treatment of septic shock symdrome |
EP94912762A EP0689380A4 (en) | 1993-03-16 | 1994-03-08 | Removal of selected factors from whole blood or its components |
CA002156721A CA2156721C (en) | 1993-03-16 | 1994-03-08 | Removal of selected factors from whole blood or its components |
JP6521097A JPH09501066A (en) | 1993-03-16 | 1994-03-08 | Removal of selected factors from whole blood or its components |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/032,357 US5437861A (en) | 1993-03-16 | 1993-03-16 | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
US08/032,357 | 1993-03-16 | ||
US20111794A | 1994-02-24 | 1994-02-24 | |
US08/201,117 | 1994-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994021124A1 true WO1994021124A1 (en) | 1994-09-29 |
Family
ID=26708317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/002541 WO1994021124A1 (en) | 1993-03-16 | 1994-03-08 | Removal of selected factors from whole blood or its components |
Country Status (6)
Country | Link |
---|---|
US (1) | US5523096A (en) |
EP (1) | EP0689380A4 (en) |
JP (1) | JPH09501066A (en) |
AU (1) | AU680897B2 (en) |
CA (1) | CA2156721C (en) |
WO (1) | WO1994021124A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058005A2 (en) * | 1999-03-26 | 2000-10-05 | Bioserv Ag | Immunoadsorber for use in sepsis therapy |
EP2671600A1 (en) * | 2012-06-08 | 2013-12-11 | Pall Corporation | Cell harvesting device and system |
US9427512B2 (en) | 2012-06-08 | 2016-08-30 | Pall Corporation | Filter device |
EP3834860A1 (en) * | 2019-12-11 | 2021-06-16 | Infomed SA | Device for extracorporeal circulation of blood |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437861A (en) * | 1993-03-16 | 1995-08-01 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
PT710126E (en) | 1993-07-30 | 2004-09-30 | Aruba Internat Pty Ltd | PLASMA DISPIPING SYSTEM |
AUPN030794A0 (en) | 1994-12-22 | 1995-01-27 | Aruba International Pty Ltd | Discontinuous plasma or serum delipidation |
JPH08257115A (en) * | 1995-03-20 | 1996-10-08 | Kanegafuchi Chem Ind Co Ltd | Adsorbent of tumor necrosis factor and adsorption removal method |
US5997496A (en) * | 1995-07-10 | 1999-12-07 | Asahi Medical Co., Ltd. | System and method of extracorporeally treating blood to alleviate the symptoms of inflammatory diseases |
US7166084B2 (en) * | 1996-09-23 | 2007-01-23 | Dsu Medical Corporation | Blood set priming method and apparatus |
US20020159995A1 (en) * | 1997-07-30 | 2002-10-31 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing |
US20020197250A1 (en) * | 2001-04-10 | 2002-12-26 | Renal Tech International | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
US20020198487A1 (en) * | 2001-04-10 | 2002-12-26 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids |
US8329388B2 (en) * | 1997-07-30 | 2012-12-11 | Cytosorbents, Inc. | Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood |
US20020197249A1 (en) * | 2001-04-10 | 2002-12-26 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products |
US5945457A (en) * | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
US6287516B1 (en) * | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
JP2000262895A (en) * | 1999-03-17 | 2000-09-26 | P Sharuma Chandora | Production of immunity adsorbent matrix and immunity adsorbent column |
US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
US6736972B1 (en) | 2000-03-24 | 2004-05-18 | Immunocept, L.L.C. | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases |
US6787040B2 (en) * | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
US20090017069A1 (en) * | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
US7407663B2 (en) | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
US7439052B2 (en) * | 2000-06-29 | 2008-10-21 | Lipid Sciences | Method of making modified immunodeficiency virus particles |
US20020197252A1 (en) * | 2001-04-10 | 2002-12-26 | Renal Tech International | Selective adsorption devices and systems |
US6878127B2 (en) | 2001-04-10 | 2005-04-12 | Renaltech International, Llc | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
EP1409108A4 (en) * | 2001-06-25 | 2007-11-14 | Lipid Sciences Inc | Hollow fiber contactor systems for removal of lipids from fluids |
US20060060520A1 (en) * | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
EP1412045A4 (en) * | 2001-06-25 | 2007-05-02 | Lipid Sciences Inc | Systems and methods using a solvent for the removal of lipids from fluids |
AU2002322284A1 (en) * | 2001-06-25 | 2003-01-08 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
US6991727B2 (en) | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
JPWO2003055545A1 (en) * | 2001-12-25 | 2005-04-28 | 株式会社カネカ | Cytokine adsorbent, adsorption removal method and adsorption removal apparatus |
EP1575507A2 (en) * | 2002-04-02 | 2005-09-21 | Scantibodies Laboratory, Inc. | Methods and devices for treating severe peripheral bacterial infections |
JP2005535394A (en) * | 2002-08-13 | 2005-11-24 | アルビオス テクノロジーズ インコーポレーティッド | Selective plasma exchange method |
US20040106556A1 (en) * | 2002-08-26 | 2004-06-03 | Yanhong Zhu | Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles |
PT2368565E (en) * | 2003-07-03 | 2015-10-19 | Hdl Therapeutics Inc | Enrichment of pre-beta high density lipoproteins |
US7393826B2 (en) * | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
US6960803B2 (en) * | 2003-10-23 | 2005-11-01 | Silicon Storage Technology, Inc. | Landing pad for use as a contact to a conductive spacer |
AU2005240082B2 (en) * | 2004-04-30 | 2009-07-23 | Innatus Corporation | Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients |
US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
CA3083194A1 (en) | 2017-11-22 | 2019-05-31 | Hdl Therapeutics, Inc. | Systems and methods for priming fluid circuits of a plasma processing system |
CA3087207A1 (en) | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
JP6783897B1 (en) * | 2019-05-09 | 2020-11-11 | 日機装株式会社 | Blood purification device |
CN112439397A (en) * | 2019-08-28 | 2021-03-05 | 云南师范大学 | Blood perfusion adsorbent coated and immobilized with heparin and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4059685A (en) * | 1973-03-19 | 1977-11-22 | Summa Corporation | Immobilized immunoadsorbent |
US4472303A (en) * | 1981-07-10 | 1984-09-18 | Kuraray Co., Ltd. | Blood purification method |
US4681870A (en) * | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
US4748121A (en) * | 1984-11-30 | 1988-05-31 | Ppg Industries, Inc. | Porous glass fibers with immobilized biochemically active material |
US4883765A (en) * | 1986-09-04 | 1989-11-28 | I.D.L. Int'l Diagnostic Laboratories Ltd. | Method for the quantitative determination of lipoprotein components in a body fluid and method for separating lipoproteins from blood |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3442819A (en) * | 1965-03-26 | 1969-05-06 | Mount Sinai Hospital Research | Molecular sieve coated particulate adsorbent and processes using same |
US3607857A (en) * | 1970-03-03 | 1971-09-21 | Upjohn Co | Process of removing acrinol from gamma globulin using siliceous material such as silica gel |
US4006059A (en) * | 1974-07-29 | 1977-02-01 | Purdue Research Foundation | Hydrophobic noncovalent binding of proteins to support materials |
US3998946A (en) * | 1975-04-23 | 1976-12-21 | The Regents Of The University Of Minnesota | Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same |
US4102746A (en) * | 1975-08-29 | 1978-07-25 | Amerace Corporation | Immobilized proteins |
GB1536425A (en) * | 1976-01-30 | 1978-12-20 | Nat Res Dev | Blood treatment |
US4072566A (en) * | 1976-09-27 | 1978-02-07 | Corning Glass Works | Immobilized biologically active proteins |
US4073723A (en) * | 1976-11-15 | 1978-02-14 | Swank Roy L | Anti-coagulating and filtering blood |
DE3109123A1 (en) * | 1981-03-11 | 1982-09-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Process for the covalent immobilisation of biological detoxification systems on artificial surfaces |
US4787974A (en) * | 1981-06-29 | 1988-11-29 | Ambrus Clara M | Blood purification |
JPS5928972A (en) * | 1982-08-10 | 1984-02-15 | 株式会社日本メデイカル・サブライ | Adsorbing body for purifying blood and production thereof |
JPS6158664A (en) * | 1984-08-30 | 1986-03-25 | 旭化成株式会社 | Porous glass adsorbent for ectosomatic recirculation treatment |
US4861707A (en) * | 1987-02-02 | 1989-08-29 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus antigen |
JPS63229061A (en) * | 1987-03-18 | 1988-09-22 | テルモ株式会社 | Membrane type artificial lung and its production |
DE3717951C1 (en) * | 1987-05-25 | 1988-11-24 | Shanmugam Murugavel | Use of silica gel to detoxify blood |
US4865841A (en) * | 1987-10-23 | 1989-09-12 | Imre Corporation | Methods and compositions for transient elimination of humoral immune antibodies |
US5041079A (en) * | 1987-12-04 | 1991-08-20 | Kuraray Co., Ltd. | Method for removing human immunodeficiency virus and/or its related compounds |
US4963265A (en) * | 1988-05-06 | 1990-10-16 | Applied Immunesciences, Inc. | Plasma processing device with anaphylatoxin remover |
US5022988A (en) * | 1988-05-06 | 1991-06-11 | Applied Immunesciences | Device for plasma modification--composition and remodeling |
US5055447A (en) * | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
US5437861A (en) * | 1993-03-16 | 1995-08-01 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
US5421815A (en) * | 1993-12-14 | 1995-06-06 | Nof Corporation | Method for blood dialysis using anticoagulent composition |
-
1994
- 1994-03-08 AU AU65176/94A patent/AU680897B2/en not_active Ceased
- 1994-03-08 JP JP6521097A patent/JPH09501066A/en active Pending
- 1994-03-08 WO PCT/US1994/002541 patent/WO1994021124A1/en not_active Application Discontinuation
- 1994-03-08 EP EP94912762A patent/EP0689380A4/en not_active Withdrawn
- 1994-03-08 CA CA002156721A patent/CA2156721C/en not_active Expired - Fee Related
-
1995
- 1995-06-06 US US08/482,315 patent/US5523096A/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4059685A (en) * | 1973-03-19 | 1977-11-22 | Summa Corporation | Immobilized immunoadsorbent |
US4472303A (en) * | 1981-07-10 | 1984-09-18 | Kuraray Co., Ltd. | Blood purification method |
US4748121A (en) * | 1984-11-30 | 1988-05-31 | Ppg Industries, Inc. | Porous glass fibers with immobilized biochemically active material |
US4681870A (en) * | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
US4883765A (en) * | 1986-09-04 | 1989-11-28 | I.D.L. Int'l Diagnostic Laboratories Ltd. | Method for the quantitative determination of lipoprotein components in a body fluid and method for separating lipoproteins from blood |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058005A2 (en) * | 1999-03-26 | 2000-10-05 | Bioserv Ag | Immunoadsorber for use in sepsis therapy |
WO2000058005A3 (en) * | 1999-03-26 | 2001-03-29 | Bioserv Ag | Immunoadsorber for use in sepsis therapy |
EP2671600A1 (en) * | 2012-06-08 | 2013-12-11 | Pall Corporation | Cell harvesting device and system |
US9421317B2 (en) | 2012-06-08 | 2016-08-23 | Pall Corporation | Cell harvesting device and system |
US9427512B2 (en) | 2012-06-08 | 2016-08-30 | Pall Corporation | Filter device |
EP3834860A1 (en) * | 2019-12-11 | 2021-06-16 | Infomed SA | Device for extracorporeal circulation of blood |
Also Published As
Publication number | Publication date |
---|---|
EP0689380A4 (en) | 1996-08-14 |
EP0689380A1 (en) | 1996-01-03 |
AU680897B2 (en) | 1997-08-14 |
AU6517694A (en) | 1994-10-11 |
CA2156721C (en) | 1999-06-01 |
CA2156721A1 (en) | 1994-09-29 |
US5523096A (en) | 1996-06-04 |
JPH09501066A (en) | 1997-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5730713A (en) | Removal of selected factors from whole blood or its components | |
US5523096A (en) | Removal of selected factors from whole blood or its components | |
US7846650B2 (en) | Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
JP5140567B2 (en) | Selective adsorption device and selective adsorption system | |
US7556768B2 (en) | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
US8334094B2 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products | |
EP1765433B1 (en) | Plasma detoxification and volume control system | |
US6736972B1 (en) | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases | |
JP3899128B2 (en) | Apparatus and method for biospecific removal of heparin | |
US8329388B2 (en) | Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood | |
US20050061742A1 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids | |
US6878127B2 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
Bernstein et al. | Extracorporeal enzymatic heparin removal: Use in a sheep dialysis model | |
US20210008269A1 (en) | Method for treating drug intoxication | |
JPH07108315B2 (en) | Blood purification device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2156721 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994912762 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994912762 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994912762 Country of ref document: EP |